[{"id":"df928720-03da-42b3-a83f-dd24e4e18afa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05695898","created_at":"2023-01-25T18:00:06.300Z","updated_at":"2024-07-02T16:35:12.998Z","phase":"Phase 1","brief_title":"XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy","source_id_and_acronym":"NCT05695898","lead_sponsor":"University of California, San Francisco","biomarkers":" PD-L1 • BRAF • LAG3","pipe":"","alterations":" ","tags":["PD-L1 • BRAF • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bavunalimab (XmAb22841) • izuralimab (XmAb23104)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/28/2023","start_date":" 02/28/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-25"},{"id":"82abbfb4-9687-48c6-8688-0f55469253e1","acronym":"DUET-3","url":"https://clinicaltrials.gov/study/NCT03752398","created_at":"2021-01-18T18:26:08.585Z","updated_at":"2024-07-02T16:35:19.743Z","phase":"Phase 1","brief_title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","source_id_and_acronym":"NCT03752398 - DUET-3","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • izuralimab (XmAb23104)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-12"}]